EUVIMEDEUVIMED entdecken
Crossref

Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis

Jesús Troya iD, Guillermo Pousada, Ignacio de Los Santos iD, Rafael Micán iD, Carlos Galera iD, José Sanz iD, Alberto Díaz de Santiago iD, José Antonio Iribarren, Estela Moreno iD, Miguel Ángel Morán, Julia Gómez, Pepa Galindo iD und 3 weitere

HIV Medicine · 12.11.2026

DOI: 10.1111/hiv.70365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 12.11.2026. Verfasst von Jesús Troya und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Infanta Leonor, Madrid, Spain. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).

Methods

Three Spanish cohorts of adults with baseline HIV‐RNA

Schlagwörter

Stichwörter der Autor:innen

CD4+ T‐cell countHIVmaintenance therapyobservational studypropensity score

Autor:innen und Institutionen

  • Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.
  • Hospital Universitario La Princesa, Madrid, Spain.
  • Hospital Universitario La Paz, Madrid, Spain.
  • Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Hospital Universitario Príncipe de Asturias, Madrid, Spain.

ORCID-Profile: Jesús Troya, Ignacio de Los Santos, Rafael Micán, Carlos Galera, José Sanz, Alberto Díaz de Santiago, Estela Moreno, Pepa Galindo, Cristina Martín, Carlos Dueñas, Luis Buzón-Martín

Förderung

  • Gilead Sciences

Zitieren

APA

Troya, J., Pousada, G., de Los Santos, I., Micán, R., Galera, C., Sanz, J., de Santiago, A. D., Iribarren, J. A., Moreno, E., Morán, M. Á., Gómez, J., Galindo, P., Martín, C., Dueñas, C., & Buzón-Martín, L. (2026). Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis. HIV Medicine. https://doi.org/10.1111/hiv.70365

Vancouver

Troya J, Pousada G, de Los Santos I, Micán R, Galera C, Sanz J, et al. Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis. HIV Medicine. 2026. doi:10.1111/hiv.70365

BibTeX
@article{Troya2026,
  author = {Troya, Jesús and Pousada, Guillermo and de Los Santos, Ignacio and Micán, Rafael and Galera, Carlos and Sanz, José and de Santiago, Alberto Díaz and Iribarren, José Antonio and Moreno, Estela and Morán, Miguel Ángel and Gómez, Julia and Galindo, Pepa and Martín, Cristina and Dueñas, Carlos and Buzón-Martín, Luis},
  title = {Immune outcomes with dolutegravir‐based dual therapy versus bictegravir‐based triple therapy: A multinomial propensity score analysis},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70365}
}
Kostenlos starten →